As the role of chronic kidney disease (CKD) in different types of heart failure (HF) is poorly understood, our aim was to compare CKD in HF with preserved (HFpEF), mid-range (HFmrEF), and reduced ejection fraction (HFrEF) with regard to prevalence, associations and prognostic role. 
Introduction
Chronic kidney disease (CKD) is common in heart failure (HF) and is associated with worse outcomes.
1,2 The complex haemodynamic and neurohormonal relationship between the heart and kidney constitutes the cardiorenal syndrome. 3 The increased mortality with CKD and worsening renal function has been well described in HF with reduced ejection fraction (HFrEF). 4 Similarly, numerous trials in HFrEF have established the efficacy and safety of neurohormonal antagonist drugs, and the criteria for renal function and potassium levels are available to guide clinicians in prescribing and titrating these drugs. 5 In contrast, HF with preserved ejection fraction (HFpEF), variably defined as ejection fraction (EF) >40-55%, is a heterogeneous syndrome that remains poorly understood and without evidence-based treatment. 5, 6 Heart failure with mid-range ejection fraction (HFmrEF) is increasingly viewed as a separate category 7, 8 and was defined as a distinct EF 40-49% phenotype in particular need of further study in the recent European Society of Cardiology (ESC) HF guidelines. 5 HFmrEF may be more similar to HFpEF or to HFrEF, it may be a transition between the two, or it may be a distinct syndrome. HFpEF may be a separate syndrome dominated by diastolic dysfunction, similar to HFmrEF and HFrEF or merely a manifestation primarily of age and age-related co-morbidities, obesity, and deconditioning. 9, 10 The link between CKD and HFmrEF and HFpEF is poorly understood. There are no studies specifically comparing HFpEF, HFmrEF and HFrEF with regard to CKD. Earlier reports did not differentiate between HFpEF and HFrEF, 11 included highly selected patients, 12 examined only short-term prognosis, 13 or CKD was examined only as part of a general co-morbidity burden.
14 Thus, the aim was to perform the first large, generalizable comprehensive comparison of CKD in HFpEF, HFmrEF, and HFrEF with regard to prevalence, clinical correlates and long-term prognostic role.
Methods

Patients and baseline characteristics
The Swedish HF registry (SwedeHF) has been described previously. 15 It is a web-based national quality register that has enrolled unselected HF patients since 2000. The protocol, registration form and annual report are available online (http://www.SwedeHF.se).
Inclusion criterion is clinician-judged HF, and approximately 80 variables are recorded at discharge from hospital or during outpatient visits to physician or healthcare team. Individual patient consent is not required but patients are informed of entry into national quality registers and allowed to opt out.
The registry includes variables concerning baseline description of patients, including risk factors, history of heart disease, cardiac diagnostics and interventions, medication, and laboratory tests.
Serum creatinine was obtained at discharge for hospitalized patients and at the closest date preceding an outpatient visit. Glomerular filtration rate was estimated (eGFR) with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 16 CKD was defined as an eGFR ≤60 mL/min.1.73 m 2 , in line with earlier studies of HF and CKD. 4 Ejection fraction was obtained from the latest available measurement and method according to local practice (in Sweden generally echocardiography with the Simpson method).
We defined HFpEF as left ventricular ejection fraction (LVEF) ≥50%, HFmrEF as LVEF 40-49%, and HFrEF as LVEF <40%, according to contemporary recommendations. 5, 17 The study conforms to the declaration of Helsinki and was approved by the regional ethics review board in Linköping.
Dependent variables and outcome
In assessing the association between baseline variables and baseline CKD, the dependent variable was CKD. In assessing the association between CKD and prognosis, the dependent outcome was death from any cause. Failure registry (SwedeHF). EF, ejection fraction; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction. the Swedish population registry, which includes the vital status of all Swedish citizens and permanent residents.
Statistics
Descriptive continuous variables are presented as median and interquartile range (IQR) and categorical variables are presented as counts and proportions (%). Comparisons were made by Pearson chi-square for proportions and Mann-Whitney test for continuous variables. The index date was date of admission to hospital or date of outpatient visit, respectively. Patients with missing data for age or creatinine, creatinine measurement methods not traceable to isotope dilution mass spectroscopy standards, missing data of EF, repeat registrations or patients that died during hospitalization were excluded. For remaining variables missing data were handled by multiple imputation (n = 10) using the same 28 variables as in the multivariable analyses below.
Associations between baseline variables and baseline CKD were assessed with multivariable logistic regression using a total of 28 clinically relevant variables: age, gender, civil status, care in cardiology ward, hypertension, diabetes, smoking, ischaemic heart disease, atrial fibrillation, valvular heart disease, pulmonary disease, revascularization, hospitalization at diagnosis, HF duration >6 months, New York Heart Association (NYHA) class, haemoglobin, systolic blood pressure, heart rate, renin-angiotensin-aldosterone system (RAAS) blockers, beta-blockers, aldosterone antagonists, digoxin, statins, nitrates, oral CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; f-u, follow-up; HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IHD, ischaemic heart disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; VHD, valvular heart disease. P-values comparing eGFR ≥60 vs. <60 mL/min.1.73 m 2 within each ejection fraction group: * P < 0.01, ** P < 0.05, *** not significant (P > 0.05). † The 28 variables in the multiple imputation and multivariable analyses.
anticoagulants, antiplatelet treatment, specialist follow-up, and HF team follow-up. Pre-selected variables of interest were illustrated in a Forest plot. When examining the association between continuous variables and CKD, age was divided into three categories: <65, 65-79, and ≥80 years, heart rate into three categories: <70, 70-90, and ≥90 b.p.m., systolic blood pressure into three categories: >140,
100-139
, and <100 mmHg, and haemoglobin into three categories: >150, 120-149, and <120 g/L.
Crude survival was assessed and illustrated with Kaplan-Meier analyses.
Univariate and multivariate Cox proportional hazard regression analysis was used to examine the association between CKD and 
Results
Patients and baselines characteristics
From May 11, 2000 until October 3, 2013, a total of 88 317 registrations occurred in SwedeHF. After excluding repeat registrations and applying the exclusion criteria above, a total of 40 230 unique patients were included. Of these, 8875 (22%) were classified as HFpEF, 8374 (21%) as HFmrEF, and 22 981 (57%) as HFrEF (Figure 1 ).
There was a higher prevalence of CKD in HFpEF than in HFmrEF and HFrEF (56% vs. 48% and 45%, respectively, P < 0.001 Table S1 ).
There was more hypertension, atrial fibrillation and valvular heart disease in HFpEF while there was more ischaemic heart disease and revascularization in HFmrEF and HFrEF, all increasing with worse kidney function. There were no differences in proportions of diabetes between HFpEF, HFmrEF, and HFrEF, but higher proportions in those with CKD. Patients with worse kidney function more often had HF with longer duration and were in a more severe NYHA class regardless of EF.
In HFpEF and HFmrEF patients had higher systolic blood pressures and in HFpEF slightly higher body mass index, with no major differences in the presence vs. absence of CKD ( Table 2 and the  Supplementary material online, Table S2 ). It was found that HFpEF had lower haemoglobin level than HFmrEF and HFrEF and in all groups the haemoglobin level decreased with lower kidney function. N-Terminal pro-brain natriuretic peptide (NT-proBNP) level was lowest in HFpEF and HFmrEF and highest in HFrEF, and approximately the double in CKD vs. non-CKD, regardless of EF. In all EF categories, CKD was associated with greater age, co-morbidity, and severity of HF.
There was lower use of angiotensin-converting enzyme (ACE)-inhibitors and angiotensin receptor blockers (ARBs) in CKD and with progressive renal dysfunction, but for aldosterone antagonists this was true only at the lowest eGFR ( Table 2 and the  Supplementary material online, Table S2 ).
Associations between covariates and chronic kidney disease
To elucidate the independent risk markers and potential risk factors for CKD, the independent associations were assessed between important baseline covariates and CKD, separately in HFpEF, HFmrEF, and HFrEF (Figure 2 ). There were numerous baseline variables independently associated with CKD, including greater age, female sex, hypertension, diabetes, longer duration of HF, and NYHA class. Anaemia was strongly associated with CKD, whereas ischaemic heart disease and atrial fibrillation were not strongly associated with CKD after adjustments for covariates. Notably, the associations with CKD changed somewhat after multivariable adjustment, but were similar regardless of EF category. As expected, prescription of RAAS blockade was associated with lower odds of having CKD while beta blockers were associated with higher odds (see the Supplementary material online, Tables  S3-S5 ).
Associations between chronic kidney disease and mortality
Over a median (IQR) follow-up of 900 (369-1669) days, there were 10 862 deaths overall. Within each EF group, patients with CKD had a worse outcome both in the short and long term (Table 3, Figure 3 ). In the crude survival analyses patients with HFpEF, HFmrEF, and HFrEF had similar poor prognosis in the presence of CKD, whereas in the absence of CKD, HFpEF had higher 1-year, 5-year, overall, and long-term mortality compared with HFmrEF and HFrEF. Accordingly, in the unadjusted analysis, CKD was less strongly associated with mortality in HFpEF than in HFmrEF and HFrEF and remained less associated with mortality after multiple adjustments (P for interaction <0.001), although the effect of adjustment was greater in those with HFmrEF and HFrEF than for HFpEF ( Table 4 ). In patients with CKD, there was a stronger association between renal function and mortality in patients with HFmrEF and HFrEF (see the Supplementary material online, Figure S1 ).
In ROC analyses of 1-year mortality, the prognostic discrimination of kidney function, measured as eGFR as a continuous variable in area under the curve analysis, was larger in HFrEF and HFmrEF than in HFpEF patients (Figure 4) . chronic kidney disease. CI, confidence interval; IHD, ischaemic heart disease; Hb, haemoglobin; HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NYHA, New York Heart Association; OR, odds ratio.
Discussion
according to the new HF types in the recent ESC HF guidelines. 5 There were several important findings. The associations between CKD and characteristics such as greater age, female sex, and greater severity of HF were similar in the three groups. However, HFpEF stood out as different compared with HFmrEF and HFrEF, which were more similar. In HFpEF, CKD was more common but less important, with a weaker association with mortality, less modification of risk by conventional HF risk markers, and with a less discriminatory power for mortality. In the present study, more than 50% had HFrEF. The proportions of HFpEF and HFmrEF were equally common, with the proportion of HFpEF being slightly lower than that in earlier studies. 18, 19 We found a proportion of CKD in HFpEF of 56%, which was higher than 
Figure 3
Kaplan-Meier curves for long-term mortality in heart failure with preserved (HFpEF), mid-range (HFmrEF), and reduced ejection fraction (HFrEF). eGFR, estimated glomerular filtration rate.
in HFrEF and HFmrEF and higher than that seen previously, 14, 20 and consistent with the unselective nature of SwedeHF compared with clinical trial databases.
Our study differs from previous reports, in which the HFmrEF has either been excluded or grouped with the HFpEF or HFrEF population. 6, 14, 21 Instead, the present study provides a novel and detailed description of the HFmrEF group, where many clinical characteristics such as age, proportion of females, and hypertension were on a continuum between HFpEF and HFrEF but certain characteristics, such as ischaemic and valvular heart disease, were distinctly more similar to HFrEF than to HFpEF.
As seen in other studies, the HFpEF population was older, more often female, had more co-morbidities, more often included a hospitalization, and more often were living alone-all signs consistent with frailty, which may contribute to higher mortality in HFpEF than in HFmrEF and HFrEF among patients without CKD. diabetes, an important contributor to CKD, which has been observed in varying proportions in previous studies. 14,23 However, this does not rule out the possibility that the mechanisms by which diabetes may contribute to HF may vary according to EF.
When examining the associations between CKD and different covariates in the three types of HF, we found almost similar associations between baseline characteristics and CKD in the three EF groups after multivariable adjustments. Age was the most important variable associated with CKD even after multiple adjustments; this is not unexpected as age is indeed a component of the calculation of eGFR. Haemoglobin as part of the cardiorenal syndrome showed an independent association with CKD, as did diabetes and hypertension. A possible explanation is that drivers of CKD are similar in HF regardless of EF. However, the effect of CKD in the different EF groups regarding severity and outcomes may still differ. CI, confidence interval; HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio. P-value for all <0.001. * Age, gender, civil status, cardiology ward, specialist follow-up, heart failure team follow-up, hypertension, diabetes, smoking, ischaemic heart disease, atrial fibrillation, valvular heart disease, pulmonary disease, revascularization, hospitalization at diagnosis, heart failure duration >6 months, New York Heart Association class, haemoglobin, systolic blood pressure, heart rate, renin-angiotensin-aldosterone system blockers, beta blockers, aldosterone antagonists, digoxin, statins, nitrates, oral anticoagulants, and antiplatelet treatment.
Figure 4
Estimated glomerular filtration rate as predictor of 1-year mortality: receiver operating characteristic (ROC) curves and area under the curve. HFmrEF, heart failure with mid-range ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.
The literature concerning mortality in HFpEF and CKD is inconsistent. Chronic kidney disease was found to be a more powerful predictor of death in patients with HFpEF than in HFrEF in the extensive meta-analysis of Damman et al. 4 with over 80 000 patients and was thought to be caused by underlying disease such as hypertension and diabetes, associated with impaired GFR and worse outcome. This was however contradicted by the Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) meta-analysis showing a lower mortality rate and lower association between CKD and death in patients with HFpEF than in HFrEF, which is in line with our results. 4, 24, 25 In the present study, CKD was strongly associated with mortality in all EF groups, in keeping with earlier studies. 4 In the crude analyses of patients with CKD, there were no differences in shortand long-term mortality between the three EF groups. In the absence of CKD, HFpEF was associated with considerably greater mortality than HFmrEF or HFrEF. This implies similarities between HFrEF and HFmrEF and a distinction vs. HFpEF.
. The risk associated with CKD was lower in HFpEF in both univariate and multivariate analyses but was reduced by less when adjusting for multiple covariates. Together, these findings suggest that while CKD is common in HFpEF, it represents one of many co-morbidities and may have more of a bystander role than it does in HFmrEF or HFrEF, where it may be more intricately tied to the HF syndrome itself and its severity.
Although the present study improves the understanding of CKD in different types of HF, we can only speculate about underlying mechanisms. In HFrEF the cardiorenal syndrome has been well described. The presence of CKD may capture patients with a more advanced HF stage. Chronic kidney disease seems to be secondary to both backward and forward failure, sympathetic and neurohormonal activation, and contributes to further cardiac deterioration. secondary to the same risk factors. Earlier studies have shown that HFpEF seems to be associated with endothelial dysfunction and inflammation, and a new paradigm has been proposed for HFpEF where co-morbidity induces an inflammatory state with microvascular dysfunction potentially leading to both cardiac and renal fibrosis. 26 -28 Increased central venous pressure has been found to be associated with impaired renal function both in patients with reduced and preserved EF. 29 It has been proposed that HFpEF patients are more susceptible to low blood pressure regarding renal function, being more preload dependent and having more autonomic dysfunction with ventricular and arterial stiffness. 28 This may contribute to the observed higher proportion of CKD in HFpEF in our material.
On the other hand, CKD may contribute to the development of HFpEF as greater age, urine albumin, cystatin C have been found to be strong risk factors for new-onset HFpEF 30 and albuminuria in combination with reduced eGFR is associated with both hypertrophy and cardiac remodelling. 26 Finally, the lower use of RAAS inhibitor therapy with declining renal function was not unexpected but raises several issues. Although trials have excluded and guidelines do not recommend the use of RAAS inhibitors in patients with eGFR <30 mL/min.1.73 m 2 , 5 previous observational data suggest RAAS inhibitor therapy may be associated with improved outcomes even in severe renal failure, 31 a question that is particularly relevant with the emergence of novel potassium binders.
Furthermore, the association between use of RAAS inhibitors and outcomes in HFpEF, and in particular HFmrEF, continues to be an important area of study, and the potential interactions with CKD are particularly relevant for future trial design.
Limitations
As a descriptive real-life study the present study was not designed to draw direct conclusions about directions of associations and causality. We defined CKD as eGFR ≤60 mL/min.1.73 m 2 , even though the current actual definition of kidney disease also involves measurement of albuminuria. 32 This may have led to some misclassification, but is in line with earlier studies of HF and CKD. 4 All eGFR data were at baseline only and we did not have access to longitudinal changes. Although SwedeHF is nationwide, coverage is incomplete and our cohort may not be completely generalizable to the entire Swedish HF population or to other geographical settings. Some variables entering multivariable models had missing data, which was handled by multiple imputation. There may have been some misclassification of EF in the echocardiographic measurements, as all EF data were baseline data, not capturing potential changes over time, and the EF measurements were not adjudicated. However, overall, the present study reflects prevalence and prognosis as defined in the current daily practice. in HFmrEF and HFrEF, it was less strongly associated with mortality and had less prognostic discrimination in this subset of patients.
Conclusion
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